⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
cis P-tau Immunotherapy
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-12 — The Pin1-cis P-tau Axis: A Key Common Early Pathogenic Driver, Biomarker and Therapeutic Target Across Neurodegenerative, Traumatic, and Vascular Cognitive Disorders.: Review-level synthesis (2024) proposes the Pin1–cis P-tau axis as a shared early driver, biomarker, and cis-specific immunotherapy target across AD, TBI/CTE, and vascular cognitive disorders — consolidating rationale but adding no new primary human outcome data. [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
The Pin1-cis P-tau Axis: A Key Common Early Pathogenic Driver, Biomarker and Therapeutic Target Across Neurodegenerative, Traumatic, and Vascular Cognitive Disorders.
12-sep-2026
novelty 3
per-area 3
strengthens